You are here: Industry Insights > Antengene

News List

Qiming's Portfolio Company Antengene Lists on Main Board of HKEX prnasia
November 20, 2020
Qiming's portfolio company Antengene officially listed on the Main Board of The Stock Exchange of Hong Kong, S.A.R., China Limited today.
Antengene, WuXi Biologics Ink Innovative Oncology R&D Alliance contractpharma
October 14, 2020
Partner for the development and production of novel drugs, and to jointly promote R&D of innovative oncology therapies.
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization prnasia
July 20, 2020
Antengene Corporation, a leading innovative hematology and oncology-focused biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and best-in-class therapies, today announced that it has successfully clos
Celgene invests in Chinese biotech Antengene again fiercebiotech
January 04, 2019
China’s Antengene has raised another $120 million in a second-round financing, with partner Celgene contributing to the tally....
China’s Antengene raises $120m to boost drug development pharmaceutical-technology
January 03, 2019
Chinese biopharmaceutical firm Antengene has raised $120m in a series B funding round led by Boyu Capital and FountainVest to support the development and commercialisation of new therapeutics.
China’s Antengene raises $120m to boost drug development pharmaceutical-technology
January 03, 2019
Chinese biopharmaceutical firm Antengene has raised $120m in a series B funding round led by Boyu Capital and FountainVest to support the development and commercialisation of new therapeutics.....

Previous page 1 2 3 4 5 Next page